<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661089</url>
  </required_header>
  <id_info>
    <org_study_id>0335-006</org_study_id>
    <nct_id>NCT00661089</nct_id>
  </id_info>
  <brief_title>Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity</brief_title>
  <official_title>&quot;A Randomized Double-Blind Placebo-Controlled Trial of Botulinum Toxin Type A (BOTOX ) in the Treatment of Hemiplegic Shoulder Pain and Spasticity&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shirley Ryan AbilityLab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shirley Ryan AbilityLab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether botulinum toxin type A injected into muscles
      around the shoulder is effective in treating shoulder pain and improving function in patients
      with shoulder pain and involuntary muscle tightness after a stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with shoulder pain and spasticity at the shoulder following a stroke resulting in
      hemiplegia are eligible for participation. Following an initial screening visit involving a
      history and physical examination, subjects will be entered in to the study if they have
      significant spasticity of shoulder internal rotation/adduction associated with pain rated at
      least a 4 on the VAS for pain. Subjects will also be given a cognitive screening in which
      they will be asked to rate pain in hypothetical situations.

      Shoulder pain is a frequent complication following hemiplegic stroke, and may result in
      further disability. Spasticity is also a complication following stroke . Botulinum toxin is
      used in the treatment of post-stroke spasticity and may also have pain modulating effects.
      Participants in this study will be asked to make total of 6 visits over a period of
      approximately 13 weeks. Eligible subjects will be randomized to 100 to 200 units of botulinum
      toxin type injected into the pectoralis major at the second visit. If there is significant
      spasticity for shoulder extension, subjects will also receive injections into the teres
      major. Subjects will be followed up with assessments of pain, functioning, active and passive
      range of motion and depression following the initial injection. At the 12 weeks post
      injection visit, the blinding will be broken and subjects initially injected with placebo
      will be injected with the active drug. This will be done to give all subjects an opportunity
      to receive the active drug, as well as to assess the effects of any differences with delayed
      treatment. All subjects will return 4 weeks later to repeat the same assessments above.
      Subjects will be called at one year post study enrollment for repeat pain ratings and for
      information regarding subsequent treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Rating From Baseline to Four Weeks</measure>
    <time_frame>baseline and four weeks</time_frame>
    <description>Change scores from patient ratings VAS on mm scale for worst pain, averaged over a week for ratings performed at baseline and week four. Scale range 0-100 mm. 0= No pain, 100= worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disability Assessment Scale for Hygiene</measure>
    <time_frame>baseline and 4 weeks post injection</time_frame>
    <description>Subject rating of scores on the Disability Assessment Scale Range 0-3, 0= no disability, 3= severe disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Don a Pull Over Shirt</measure>
    <time_frame>2,4,12, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Perform Hygiene Rating</measure>
    <time_frame>2,4,12, and 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Post-stroke Shoulder Pain and Spasticity</condition>
  <arm_group>
    <arm_group_label>Intramuscular OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Placebo (Saline)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A - OnabotulinumtoxinA</intervention_name>
    <description>100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.</description>
    <arm_group_label>Intramuscular OnabotulinumtoxinA</arm_group_label>
    <other_name>BOTOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Saline)</intervention_name>
    <description>Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.</description>
    <arm_group_label>Intramuscular Placebo (Saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post stroke greater than 2 months

          -  Shoulder pain despite PT/OT interventions

          -  Weight greater than 88 lbs

          -  Stable medically

          -  Spasticity

        Exclusion Criteria:

          -  Myasthenia gravis or other medical conditions that preclude use of botulinum toxin

          -  Pregnancy

          -  Infection or dermatologic conditions at the injection site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Marciniak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shirley Ryan AbilityLab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehabilitation Institute of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marciniak CM, Harvey RL, Gagnon CM, Duraski SA, Denby FA, McCarty S, Bravi LA, Polo KM, Fierstein KM. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial. Am J Phys Med Rehabil. 2012 Dec;91(12):1007-19. doi: 10.1097/PHM.0b013e31826ecb02.</citation>
    <PMID>23064478</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>October 1, 2011</results_first_submitted>
  <results_first_submitted_qc>January 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2012</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shirley Ryan AbilityLab</investigator_affiliation>
    <investigator_full_name>Christina Marciniak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>shoulder pain</keyword>
  <keyword>spasticity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>onabotulinumtoxinA Injection</title>
          <description>Botulinum Toxin injected at second visit</description>
        </group>
        <group group_id="P2">
          <title>Saline Injection</title>
          <description>Receives placebo injections following randomization (Saline).Delayed treatment group.
Blind broken and receives botulinum toxin at week 12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>1 subject withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>death at 8 weeks due to new stroke</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>onabotulinumtoxinA Injection</title>
          <description>Botulinum Toxin injected at second visit</description>
        </group>
        <group group_id="B2">
          <title>Saline Injection</title>
          <description>Receives placebo injections following randomization (Saline).Delayed treatment group.
Blind broken and receives botulinum toxin at week 12</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="7.8"/>
                    <measurement group_id="B2" value="58.9" spread="10.3"/>
                    <measurement group_id="B3" value="60.00" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disability Assessment Scale for Hygiene</title>
        <description>Subject rating of scores on the Disability Assessment Scale Range 0-3, 0= no disability, 3= severe disability</description>
        <time_frame>baseline and 4 weeks post injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Group recieved saline injections intramuscularly of equivalent volume</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Injection</title>
            <description>Group received botulinum toxin type A (Botox) in the pectoralis and teres major muscles</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disability Assessment Scale for Hygiene</title>
          <description>Subject rating of scores on the Disability Assessment Scale Range 0-3, 0= no disability, 3= severe disability</description>
          <units>units on a scale from 0-3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-1.0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Don a Pull Over Shirt</title>
        <time_frame>2,4,12, and 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ability to Perform Hygiene Rating</title>
        <time_frame>2,4,12, and 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Rating From Baseline to Four Weeks</title>
        <description>Change scores from patient ratings VAS on mm scale for worst pain, averaged over a week for ratings performed at baseline and week four. Scale range 0-100 mm. 0= No pain, 100= worst pain</description>
        <time_frame>baseline and four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Group received saline injections intramuscularly of equivalent volume</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Injection</title>
            <description>Group received botulinum toxin type A (Botox) in the pectoralis and teres major muscles</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Rating From Baseline to Four Weeks</title>
          <description>Change scores from patient ratings VAS on mm scale for worst pain, averaged over a week for ratings performed at baseline and week four. Scale range 0-100 mm. 0= No pain, 100= worst pain</description>
          <units>units on a scale 0-100mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.88" lower_limit="-69.90" upper_limit="2.16"/>
                    <measurement group_id="O2" value="-18.64" lower_limit="-29.73" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment through 12 weeks post injection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>onabotulinumtoxinA Injection</title>
          <description>Botulinum Toxin injected at second visit</description>
        </group>
        <group group_id="E2">
          <title>Saline Injection</title>
          <description>Receives placebo injections following randomization (Saline).Delayed treatment group.
Blind broken and receives botulinum toxin at week 12</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Anemia requiring hospitalization and transfusion</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <description>Rectal bleeding requiring hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>New Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Subjects were asked at each visit for any adverse effects. 1 subject with UTI requiring hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <description>Depressive symptoms noted on Beck Depression, referred to psychology</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Lower urinary tract infection</sub_title>
                <description>Urinary tract infection not requiring hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Best and Worst pain collected, which may have limited the ability to detect overall pain. At the time of enrollment, subjects were on average very impaired by the Fugl-Meyer Scale measure, and pain on average had been present for several years.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Christina Marciniak</name_or_title>
      <organization>The Rehabilitation Institute of Chicago</organization>
      <phone>312-238-1000</phone>
      <email>cmarciniak@ric.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

